Table 1 Demographic and clinicopathological characteristics of the study population
From: PPP2R1A mutations portend improved survival after cancer immunotherapy
Characteristics | Mutated PPP2R1A (n = 11) | Wild-type PPP2R1A (n = 23) | P |
|---|---|---|---|
Age at consent, median (range) | 55.0 (46.0–72.0) | 57.0 (36.0–78.0) | 0.954a |
Arm of trial, n (%) | 0.529 | ||
NCT03026062 | |||
Sequential | 1 (9.1) | 4 (17.4) | |
Combination | 9 (81.8) | 19 (82.6) | |
NCT01928394 | |||
Combination | 1 (9.1) | 0 (0.0) | |
Previous lines of therapy, median (range) | 2.0 (1.0–8.0) | 2.0 (1.0–9.0) | 0.938b |
Platinum response, n (%) | 1.000 | ||
Platinum resistant | 10 (90.9) | 20 (87.0) | |
Platinum refractory | 1 (9.1) | 3 (13.0) | |
Race, n (%) | 0.577 | ||
White | 8 (72.7) | 19 (82.6) | |
Asian | 3 (27.3) | 3 (13.0) | |
Other | 0 (0.0) | 1 (4.3) | |
BRCA status, n (%) | 0.324 | ||
Somatic mutation (BRCA1) | 1 (9.1) | 0 (0.0) | |
Wild type | 10 (90.9) | 23 (100.0) | |
Microsatellite stability status, n (%) | 0.549 | ||
MSIhigh | 0 (0.0) | 1 (4.3) | |
MSS | 10 (90.9) | 22 (95.7) | |
Unknown | 1 (9.1) | 0 (0.0) | |
PD-L1 status, n (%) | 0.114 | ||
Positive | 3 (27.3) | 13 (56.5) | |
Negative | 4 (36.4) | 8 (34.8) | |
Unknown | 4 (36.4) | 2 (8.7) | |
AKT alteration present, n (%) | 0.280 | ||
Yes | 0 (0.0) | 4 (17.4) | |
No | 11 (100.0) | 19 (82.6) | |
ARID1A mutation present, n (%) | 0.682 | ||
Yes | 9 (81.8) | 16 (69.6) | |
No | 2 (18.2) | 7 (30.4) | |
PIK3CA mutation present, n (%) | 0.717 | ||
Yes | 5 (45.5) | 13 (56.5) | |
No | 6 (54.5) | 10 (43.5) | |
Grade 3 or higher irAE | 0.079 | ||
No grade 3 or higher irAE | 6 (54.5) | 20 (87.0) | |
Any grade 3 or higher irAE | 5 (45.5) | 3 (13.0) |
